Exosens Consolidates Its Brands Photonis, Xenics, and Telops Under a Single Banner
Exosens announced on Wednesday the gradual consolidation of all its brands under the Exosens umbrella. This change comes nearly two years after the group's IPO and continues its development since this pivotal milestone.
Products currently marketed under the brands Photonis, Xenics, El-Mul, Telops, Noxant, Phasics, and Emberion will gradually transition to the Exosens brand. This unification aims to provide customers and partners with a simpler and more coherent understanding of the group's offerings, while allowing all products to benefit from the strength and reputation of the Exosens brand on an international scale.
Since its IPO, Exosens has increased its visibility in its markets and continued its growth strategy, both organically and through targeted acquisitions. The group has integrated technological expertise and developed a portfolio of solutions covering amplification, detection, and imaging.
Positioning in Critical Markets
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
This momentum has enabled the group to strengthen its positions in markets such as Defense, Nuclear, Life Sciences, and Industrial Control, while integrating teams, technologies, and complementary product portfolios. According to Paul Ryckaert, Chief Strategy Officer of Exosens, this step marks a new phase in the transformation of the group and affirms the coherence of its offering by bringing together the products under a single brand.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
